Evogene Ltd. (EVGN) Income Statement
EVGN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsEVGN revenue and net income
Where EVGN's revenue goes
2025Each bar shows an amount and its share of revenue. EVGN kept −220.2% of revenue as net income.
EVGN profit margins
EVGN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −30.9% | +32.0% | +29.9% | −10.1% |
| Gross profit | −107.5% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
EVGN quarterly EPS vs estimates
Evogene beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 19, 2026 (estimate $-0.19).
EVGN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.9M | $5.6M | $3.0M | $1.7M | $930,000 | $1.0M | $753,000 | $1.7M | $3.4M | $6.5M |
| Cost of revenue | $4.1M | $2.4M | $1.5M | $909,000 | $767,000 | $574,000 | $334,000 | $1.5M | $2.8M | $5.6M |
| Gross profit | −$241,000 | $3.2M | $1.5M | $766,000 | $163,000 | $466,000 | $419,000 | $295,000 | $536,000 | $901,000 |
| Research & development | $8.0M | $12.5M | $16.2M | $20.8M | $21.1M | $17.3M | $15.8M | $14.7M | $17.0M | $16.4M |
| Sales, general & admin | $5.8M | $9.0M | $7.5M | $10.3M | $10.0M | $8.0M | $5.8M | $5.6M | $5.5M | $5.6M |
| Total operating expenses | $13.8M | $22.0M | $23.7M | $27.7M | $31.1M | $25.3M | $21.6M | $20.3M | $22.5M | $22.0M |
| Operating income | −$14.0M | −$18.8M | −$22.2M | −$26.9M | −$31.0M | −$24.8M | −$21.2M | −$20.0M | −$21.9M | −$21.1M |
| Interest income | $356,000 | $957,000 | $631,000 | $516,000 | $1.9M | $1.6M | $759,000 | $1.4M | $2.1M | $2.4M |
| Interest expense | $1.9M | $124,000 | $171,000 | $241,000 | $403,000 | $269,000 | $354,000 | $141,000 | $129,000 | $155,000 |
| Income before taxes | −$13.5M | −$14.8M | −$21.9M | −$29.8M | −$30.4M | −$26.2M | −$19.1M | −$20.8M | −$20.8M | −$19.6M |
| Income taxes | $1,000 | $9,000 | $19,000 | $90,000 | $13,000 | $32,000 | $24,000 | $30,000 | $11,000 | $36,000 |
| Net income | −$8.5M | −$16.5M | −$23.9M | −$26.6M | −$27.8M | −$23.4M | −$18.1M | −$20.8M | −$20.8M | −$19.6M |
| EBITDA | −$12.2M | −$13.4M | −$20.5M | −$27.0M | −$27.9M | −$23.2M | −$16.0M | −$18.8M | −$18.7M | −$18.8M |
| EPS (diluted) | −$1.96 | −$3.11 | −$5.30 | −$5.77 | −$6.90 | −$3.07 | −$0.71 | −$6.13 | −$8.10 | −$7.70 |
| Gross margin | −6.3% | 57.3% | 50.0% | 45.7% | 17.5% | 44.8% | 55.6% | 16.9% | 15.9% | 13.8% |
| Operating margin | −364.2% | −337.2% | −745.5% | −1,608.4% | −3,328.3% | −2,386.0% | −2,810.9% | −1,144.2% | −649.1% | −322.5% |
| Net margin | −220.2% | −295.6% | −800.8% | −1,590.3% | −2,988.5% | −2,247.5% | −2,405.3% | −1,188.2% | −616.3% | −299.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $347,000 | $334,000 | $314,000 | $312,000 | $884,000 | $2.4M | $1.6M | $1.7M | $605,000 | $4.2M | $578,000 | $3.8M |
| Cost of revenue | $355,000 | $130,000 | $2.3M | $157,000 | $136,000 | $1.6M | $755,000 | $1.0M | $336,000 | $310,000 | $398,000 | $511,000 |
| Gross profit | −$8,000 | $204,000 | −$2.0M | $155,000 | $748,000 | $830,000 | $856,000 | $698,000 | $269,000 | $3.9M | $180,000 | $3.3M |
| Research & development | $1.2M | $1.8M | $1.8M | $1.4M | $2.3M | $3.2M | $3.4M | $3.3M | $2.9M | $4.8M | $5.5M | $5.1M |
| Sales, general & admin | $1.2M | $1.5M | $2.2M | $1.5M | $1.5M | $1.3M | $4.5M | $3.3M | $2.0M | $2.6M | $3.8M | $2.4M |
| Total operating expenses | $2.4M | $3.4M | $3.2M | $2.9M | $3.8M | $5.0M | $5.4M | $6.6M | $4.9M | $8.0M | $7.8M | $7.4M |
| Operating income | −$2.4M | −$3.1M | −$5.2M | −$2.7M | −$3.1M | −$4.1M | −$4.6M | −$5.9M | −$4.6M | −$4.1M | −$7.6M | −$4.2M |
| Interest income | $1.1M | $1.2M | $1.9M | $465,000 | $235,000 | $1.6M | $1.9M | $2.2M | $260,000 | $407,000 | $120,000 | $429,000 |
| Interest expense | $168,000 | $3.9M | $350,000 | $453,000 | $628,000 | $464,000 | $144,000 | $2.9M | $97,000 | $166,000 | $71,000 | $109,000 |
| Income before taxes | −$1.6M | −$5.9M | −$5.3M | −$2.7M | −$3.5M | −$3.0M | $2,000 | −$6.7M | −$4.6M | −$3.8M | −$7.3M | −$3.9M |
| Income taxes | — | $4,000 | — | $1,000 | $1,000 | — | $7,000 | $1,000 | $1,000 | $425,000 | −$4,000 | −$5,000 |
| Net income | −$1.8M | −$5.9M | −$5.3M | $3.9M | −$4.5M | −$2.6M | $427,000 | −$7.6M | −$5.4M | −$3.9M | −$6.6M | −$4.0M |
| EBITDA | −$2.3M | −$1.8M | −$6.5M | −$2.0M | −$2.7M | −$1.9M | −$2.5M | −$3.6M | −$4.1M | −$3.0M | −$7.5M | −$3.1M |
| EPS (diluted) | −$0.13 | −$0.61 | −$0.62 | −$0.46 | −$0.50 | −$0.38 | $0.06 | −$1.31 | −$1.06 | −$0.80 | −$1.30 | −$0.80 |
| Gross margin | −2.3% | 61.1% | −627.4% | 49.7% | 84.6% | 34.0% | 53.1% | 40.1% | 44.5% | 92.6% | 31.1% | 86.4% |
| Operating margin | −703.5% | −943.1% | −1,659.9% | −873.1% | −347.4% | −168.8% | −283.5% | −340.2% | −765.1% | −97.5% | −1,319.7% | −111.0% |
| Net margin | −509.5% | −1,757.5% | −1,690.8% | 1,241.7% | −504.8% | −105.9% | 26.5% | −438.5% | −895.7% | −92.2% | −1,142.0% | −105.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in EVGN's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
EVGN financial results
In fiscal year 2025 (ended December 31, 2025), Evogene reported revenue of $3.9 million, down 30.9% from the year before. It had a net loss of $8.5 million, a net profit margin of −220.2%. Diluted earnings per share came to −$1.96. Over five years revenue grew at an average rate of 29.9% a year.
See the EVGN stock overview for the latest quote and news, or the EVGN chart for price history and technical indicators.
EVGN income statement FAQ
What is Evogene's annual revenue?
Evogene reported total revenue of $3.9 million for fiscal year 2025, which ended on December 31, 2025. That was down 30.9% from $5.6 million the previous year.
Is Evogene profitable?
No. Evogene reported a net loss of $8.5 million in fiscal 2025, a net profit margin of −220.2%; its operating margin was −364.2%.
What is Evogene's gross margin?
Evogene's gross margin was −6.3% in fiscal 2025: for every $100 of revenue, Evogene kept $-6 after the direct cost of its products and services.
How much does Evogene spend on research and development?
Evogene spent $8.0 million on research and development in fiscal 2025, 207.5% of revenue.
How fast is Evogene growing?
Revenue grew 29.9% a year on average over the last five fiscal years, from $1.0 million to $3.9 million.
What are Evogene's earnings per share?
Evogene earned $-1.96 per diluted share in fiscal 2025, compared with $-3.11 a year earlier.
When will Evogene report its next earnings?
Evogene is expected to report results for the quarter ending September 30, 2026 on November 19, 2026 before the market opens.
When does Evogene's fiscal year end?
Evogene's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.